Health Canada approved Tagrisso (osimertinib) for patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer who have progressed on or after EGFR tyrosine kinase inhibitor therapy. Tagrisso, sponsored by AstraZeneca Canada, was granted Notice of Compliance with Conditions, based on promising evidence of clinical efficacy data, pending the results of additional...
Bits of good news for NIH flickered consistently over the past week.
